Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Payne Andrew Charles"'
Autor:
Andrea Martín-Nalda, Maria Juarez, Pere Soler-Palacín, Francesca Conti, Eric Helmer, Caterina Cancrini, Geoffrey I Johnston, Marina Cavazzana, Dionne Cain, Nieves Diaz, Marina Garcia-Prat, Despina Moshous, Maria Elena Maccari, Payne Andrew Charles, Felipe Suarez, Michaela Semeraro, Sven Kracker, Mónica Martínez-Gallo, Daisy Yuill, Silvia Di Cesare, Stephan Ehl, Maximilian Heeg, Joanne Mann, Alessandra Simonetti, Veronica Santilli
Publikováno v:
Journal of Immunology
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2020, pp.ji2000326. ⟨10.4049/jimmunol.2000326⟩
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2020, pp.ji2000326. ⟨10.4049/jimmunol.2000326⟩
Mutations in two genes can result in activated PI3Kδ syndrome (APDS), a rare immunodeficiency disease with limited therapeutic options. Seletalisib, a potent, selective PI3Kδ inhibitor, was evaluated in patients with APDS1 and APDS2. In the phase 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc73e827abe52aed5e58c98afe06cda8
https://hal.archives-ouvertes.fr/hal-03009789/document
https://hal.archives-ouvertes.fr/hal-03009789/document
Autor:
Maria Juarez, Saba Nayar, Payne Andrew Charles, Wan-Fai Ng, Nieves Diaz, Juan Sanchez Burson, Dionne Cain, Paulette Williams, Marika Kvarnström, Benjamin A Fisher, Valérie Devauchelle-Pensec, José Rosas, Giovanni Triolo, Simon J. Bowman, Xavier Mariette, Jacques-Eric Gottenberg, Giuliana Guggino, Roberto Giacomelli, Francesca Barone, Geoffrey I Johnston, Eric Helmer
Publikováno v:
Rheumatology
Rheumatology, Oxford University Press (OUP), 2020, ⟨10.1093/rheumatology/keaa410⟩
RHEUMATOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Rheumatology, Oxford University Press (OUP), 2020, ⟨10.1093/rheumatology/keaa410⟩
RHEUMATOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Objectives This phase 2 proof-of-concept study (NCT02610543) assessed efficacy, safety and effects on salivary gland inflammation of seletalisib, a potent and selective PI3Kδ inhibitor, in patients with moderate-to-severe primary Sjögren’s syndro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a4a7a49e1db4568f69115de9d4e12a
https://hal.archives-ouvertes.fr/hal-03113993
https://hal.archives-ouvertes.fr/hal-03113993
Autor:
Mark Jones, Emma Jones, Annelize Koch, Payne Andrew Charles, Eugene Healy, Rodger A. Allen, Dominique Tytgat, Mark Watling, Eric Helmer
Publikováno v:
European Journal of Clinical Pharmacology
Purpose PI3Ks are potential therapeutic targets in immune-inflammatory diseases. These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans. Methods These phase I, randomised,
Autor:
Rodger A. Allen, Payne Andrew Charles, Emma J. Haagensen, Paul Bevan, Huw D. Thomas, Lara Kevorkian, Wolfgang A. Schmalix, David R. Newell, Ross J. Maxwell
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Tumours frequently have defects in multiple oncogenic pathways, e.g. MAPK and PI3K signalling pathways, and combinations of targeted therapies may be required for optimal activity. This study evaluated the novel MEK inhibitor WX-554 and the n
Autor:
Rodger A. Allen, Charlotte G Smith, Elena Pipi, Saba Nayar, Florian Kim Kollert, Valentina Iannizzotto, Maria Juarez, Christopher D. Buckley, Roberta Priori, Fahy William Anthony, Serena Colafrancesco, Francesca Barone, David H. Gardner, Charlotte Brewer, Kelly J Hunter, Benjamin A Fisher, Payne Andrew Charles, Joana Campos, Simon J Bowman, Guido Valesini
Publikováno v:
Nayar, Saba; Campos, Joana; Smith, Charlotte G; Iannizzotto, Valentina; Gardner, David H; Colafrancesco, Serena; Pipi, Elena; Kollert, Florian Kim; Hunter, Kelly J; Brewer, Charlotte; Buckley, Christopher Dominic; Bowman, Simon J; Priori, Roberta; Valesini, Guido; Juarez, Maria; Fahy, William A; Fisher, Benjamin A; Payne, Andrew; Allen, Rodger A and Barone, Francesca (2019). Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome. Annals of the rheumatic diseases, 78(2), pp. 249-260. BMJ Publishing Group 10.1136/annrheumdis-2017-212619
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases
Sjogren’s syndrome (SS) is a chronic autoimmune disease characterised by B-cell hyper-activation and exocrine gland infiltration that results in loss of glandular function, systemic manifestations and autoantibody production. The phosphatidylinosit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e230ee551b5ff33a83e0fe7153b18fac
https://boris.unibe.ch/125140/1/249.full.pdf
https://boris.unibe.ch/125140/1/249.full.pdf
Autor:
Payne Andrew Charles, Benjamin A Fisher, Roberto Giacomelli, Nieves Diaz, Simon J. Bowman, Wan-Fai Ng, Marika Kvarnström, Juan Sánchez-Bursón, Valérie Devauchelle-Pensec, Paulette Williams, Giuliana Guggino, Saba Nayar, Geoffrey I Johnston, Francesca Barone, Eric Helmer, Xavier Mariette, Jacques-Eric Gottenberg, Maria Juarez, José Rosas, Dionne Cain
Background: Seletalisib is a potent, selective oral inhibitor of phosphoinositide-3 kinase delta (PI3Kδ). Preclinical data have shown that the PI3Kδ pathway is upregulated within salivary glands of patients with PSS and contributes to disease patho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be59b7e769d7c89d8754fc880156d10a
http://hdl.handle.net/11697/143683
http://hdl.handle.net/11697/143683
Autor:
Nataliya Yeremenko, Stevan Shaw, Ross A. Paveley, Anthony Shock, Sijia Chen, Lathees Sritharan, Lianne Kraal, Dominique Baeten, Neesha Dedi, Maria Juarez, Elizabeth Stevens, Payne Andrew Charles
Publikováno v:
Journal of autoimmunity, 111:102435. Academic Press Inc.
The delta isoform of phosphoinositide 3-kinase (PI3Kδ) regulates various lymphocyte functions. Considering the key pro-inflammatory role of IL-17A and IL-17F cytokines in psoriasis and spondyloarthritis (SpA), we investigated the potential of PI3Kδ
Autor:
Adnan Khan, Farnaz Fallah-Arani, Bart Vanderhoydonck, Judi Charlotte Neuss, Sarah Malcolm, Alfred Lammens, Richard J. Franklin, Lindsay K. Shuttleworth, Qiuya Huang, Jamie Henshall, Daniel James Ford, Mi-Yeon Jang, Shengqiao Li, Helen Tracey Horsley, Daniel Christopher Brookings, Mark Waer, Rodger A. Allen, Payne Andrew Charles, Yuan Lin, Eleanor Ward, Tom Ceska, Piet Herdewijn, Mark Jairaj, James Thomas Reuberson, Stefan Steinbacher, Mark Daniel Calmiano, Carl Brendan Doyle, Ling-Jie Gao, William R. Pitt, Jean Herman, Martin Augustin, Thierry Louat, Anant Ramrao Ghawalkar
Publikováno v:
Journal of medicinal chemistry. 61(15)
The primary target of a novel series of immunosuppressive 7-piperazin-1-ylthiazolo[5,4- d]pyrimidin-5-amines was identified as the lipid kinase, PI4KIIIβ. Evaluation of the series highlighted their poor solubility and unwanted off-target activities.
Autor:
Ciara Haddadeen, Nicole Yager, Eugene Healy, Rodger A. Allen, Mark J. Powell, Payne Andrew Charles
Publikováno v:
The Journal of investigative dermatology. 138(6)
The phosphoinositide 3-kinase (PI3K) pathway plays a key role in many cellular processes, including cell proliferation, survival, and protein synthesis, with the PI3K isoform, PI3Kδ, involved in normal T-cell development and function (Jarmin et al.,
Publikováno v:
Poster Presentations.
Background PI3Kδ is predominantly expressed in lymphocytes; the role it plays in immune disease has encouraged the development of inhibitors targeting its kinase activity. Inhibitors of PI3Kδ have been approved or are in clinical development for th